Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 370

1.

Radiotherapy and survival in prostate cancer patients: a population-based study.

Zhou EH, Ellis RJ, Cherullo E, Colussi V, Xu F, Chen WD, Gupta S, Whalen CC, Bodner D, Resnick MI, Rimm AA, Koroukian SM.

Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):15-23. doi: 10.1016/j.ijrobp.2008.04.001. Epub 2008 Jun 4.

2.

Single photon emission computerized tomography with capromab pendetide plus computerized tomography image set co-registration independently predicts biochemical failure.

Ellis RJ, Zhou EH, Fu P, Kaminsky DA, Sodee DB, Faulhaber PF, Bodner D, Resnick MI.

J Urol. 2008 May;179(5):1768-73; discussion 1773-4. doi: 10.1016/j.juro.2008.01.025. Epub 2008 Mar 17.

PMID:
18343445
3.

Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes.

Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR; Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE).

Cancer. 2008 Jan 15;112(2):307-14.

4.

Molecular imaging of NF-kappaB in prostate tissue after systemic administration of IL-1 beta.

Vykhovanets EV, Shukla S, MacLennan GT, Resnick MI, Carlsen H, Blomhoff R, Gupta S.

Prostate. 2008 Jan 1;68(1):34-41.

PMID:
18004768
5.

The practice of medicine--a business or a profession?

Resnick MI.

J Urol. 2007 Oct;178(4 Pt 1):1143. Epub 2007 Aug 14. No abstract available.

PMID:
17698124
6.

Blockade of beta-catenin signaling by plant flavonoid apigenin suppresses prostate carcinogenesis in TRAMP mice.

Shukla S, MacLennan GT, Flask CA, Fu P, Mishra A, Resnick MI, Gupta S.

Cancer Res. 2007 Jul 15;67(14):6925-35.

7.

Getting through it all.

Resnick MI.

J Urol. 2007 Jul;178(1):9. Epub 2007 May 11. No abstract available.

PMID:
17574049
8.

Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.

Shukla S, Maclennan GT, Hartman DJ, Fu P, Resnick MI, Gupta S.

Int J Cancer. 2007 Oct 1;121(7):1424-32.

9.

This month in clinical urology.

Resnick MI.

J Urol. 2007 May;177(5):1597-600. Review. No abstract available.

PMID:
17437763
10.

Rectal morbidity after permanent prostate brachytherapy with dose escalation to biologic target volumes identified by SPECT/CT fusion.

Ellis RJ, Zhou H, Kaminsky DA, Fu P, Kim EY, Sodee DB, Colussi V, Spirnak JP, Whalen CC, Resnick MI.

Brachytherapy. 2007 Apr-Jun;6(2):149-56.

PMID:
17434109
11.

This month in clinical urology.

Resnick MI.

J Urol. 2007 Apr;177(4):1215-7. No abstract available.

PMID:
17382689
12.

Pathophysiology and treatment of ureteropelvic junction obstruction.

Williams B, Tareen B, Resnick MI.

Curr Urol Rep. 2007 Mar;8(2):111-7. Review.

PMID:
17303015
13.

Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide.

Ellis RJ, Zhou H, Kim EY, Fu P, Kaminsky DA, Sodee B, Colussi V, Vance WZ, Spirnak JP, Kim C, Resnick MI.

Brachytherapy. 2007 Jan-Mar;6(1):16-25.

PMID:
17284381
14.

Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial.

Resnick MI, Roehrborn CG.

Prostate Cancer Prostatic Dis. 2007;10(2):155-9. Epub 2007 Jan 9. Erratum in: Prostate Cancer Prostatic Dis. 2008;11(2):209.

PMID:
17211442
15.

Experimental rodent models of prostatitis: limitations and potential.

Vykhovanets EV, Resnick MI, MacLennan GT, Gupta S.

Prostate Cancer Prostatic Dis. 2007;10(1):15-29. Epub 2007 Jan 2. Review.

PMID:
17199136
16.

Choices.

Resnick MI.

J Urol. 2006 Dec;176(6 Pt 1):2342. No abstract available.

PMID:
17085096
17.

Residual and recurrent disease following renal energy ablative therapy: a multi-institutional study.

Matin SF, Ahrar K, Cadeddu JA, Gervais DA, McGovern FJ, Zagoria RJ, Uzzo RG, Haaga J, Resnick MI, Kaouk J, Gill IS.

J Urol. 2006 Nov;176(5):1973-7. Erratum in: J Urol. 2008 Jun;179(6):2490. Zagoria, Ronald A [corrected to Zagoria, Ronald J].

PMID:
17070224
18.

Prostate imaging.

Resnick MI.

Curr Urol Rep. 2006 Nov;7(6):431-2. No abstract available.

PMID:
17052437
19.

Therapeutic strategies for localized prostate cancer I: surgery, ultrasound, adjuvant and neoadjuvant therapy.

Resnick MI, Crawford ED, Gleave ME, Lynch J, Mulhall JP, Pummer K, Vallancien G.

Rev Urol. 2000;2 Suppl 4:S23-9.

20.

Fibrous inflammatory pseudotumor of the bladder.

Ricchiuti DJ, Ricchiuti VS, Ricchiuti RR, Qadri AM, Resnick MI.

Rev Urol. 2000 Fall;2(4):232-5.

21.

The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study.

MacLennan GT, Eisenberg R, Fleshman RL, Taylor JM, Fu P, Resnick MI, Gupta S.

J Urol. 2006 Sep;176(3):1012-6.

PMID:
16890681
22.

The future of journals and meetings--is there one?

Resnick MI.

J Urol. 2006 Jun;175(6):1985. No abstract available.

PMID:
16697779
23.

The impact of a negative (111)indium-capromab pendetide scan before salvage radiotherapy.

ProaƱo JM, Sodee DB, Resnick MI, Einstein DB.

J Urol. 2006 May;175(5):1668-72.

PMID:
16600726
24.

Intraprostatic lymphocyte profiles in aged wistar rats with estradiol induced prostate inflammation.

Vykhovanets EV, Resnick MI, Marengo SR.

J Urol. 2006 Apr;175(4):1534-40.

PMID:
16516042
25.

Continuous infusion of oxalate by minipumps induces calcium oxalate nephrocalcinosis.

Marengo SR, Chen DH, Evan AP, Sommer AJ, Stowe NT, Ferguson DG, Resnick MI, MacLennan GT.

Urol Res. 2006 Jun;34(3):200-10. Epub 2006 Feb 15.

PMID:
16479391
26.

A novel computer based expert decision making model for prostate cancer disease management.

Richman MB, Forman EH, Bayazit Y, Einstein DB, Resnick MI, Stovsky MD.

J Urol. 2005 Dec;174(6):2310-8.

PMID:
16280831
27.

Prostate cancer: appraisal, coping, and health status.

Ahmad MM, Musil CM, Zauszniewski JA, Resnick MI.

J Gerontol Nurs. 2005 Oct;31(10):34-43.

PMID:
16262089
28.

Up-regulation of insulin-like growth factor binding protein-3 by apigenin leads to growth inhibition and apoptosis of 22Rv1 xenograft in athymic nude mice.

Shukla S, Mishra A, Fu P, MacLennan GT, Resnick MI, Gupta S.

FASEB J. 2005 Dec;19(14):2042-4. Epub 2005 Oct 17.

PMID:
16230333
29.

Radiofrequency ablation of renal tumors: past, present, and future.

McAchran SE, Lesani OA, Resnick MI.

Urology. 2005 Nov;66(5 Suppl):15-22. Review. No abstract available.

PMID:
16194702
30.
31.

Office urologic ultrasound.

McAchran SE, Dogra V, Resnick MI.

Urol Clin North Am. 2005 Aug;32(3):337-52, vii. Review. No abstract available.

PMID:
16036146
32.

What is sexual medicine?

Resnick MI.

Int J Impot Res. 2005 Sep-Oct;17(5):464.

PMID:
15988543
33.

Prostate cancer and consistency of reporting sexual histories in men over age 50.

Dennis LK, Ritchie JM, Resnick MI.

Prostate Cancer Prostatic Dis. 2005;8(3):243-7.

PMID:
15983628
34.

Update on fused capromab pendetide imaging of prostate cancer.

Sodee DB, Nelson AD, Faulhaber PF, Maclennan GT, Resnick MI, Bakale G.

Clin Prostate Cancer. 2005 Mar;3(4):230-8. Review.

PMID:
15882479
35.

How do residents manage personal finances?

Teichman JM, Cecconi PP, Bernheim BD, Novarro NK, Monga M, DaRosa D, Resnick MI; Study Group.

Am J Surg. 2005 Feb;189(2):134-9.

PMID:
15720979
36.

Constitutive activation of P I3 K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model.

Shukla S, Maclennan GT, Marengo SR, Resnick MI, Gupta S.

Prostate. 2005 Aug 1;64(3):224-39.

PMID:
15712212
38.

A conversations between Darracott Vaughan and Martin I. Resnick.

Resnick MI.

BJU Int. 2004 Dec;94(9):1207-8. No abstract available.

39.

Migration of implanted free radioactive seeds for adenocarcinoma of the prostate using a Mick applicator.

Kunos CA, Resnick MI, Kinsella TJ, Ellis RJ.

Brachytherapy. 2004;3(2):71-7.

PMID:
15374538
40.

The medical malpractice crisis.

Resnick MI.

J Urol. 2004 Oct;172(4 Pt 1):1241. No abstract available.

PMID:
15371815
41.

Phase II clinical trial of interactive MR imaging-guided interstitial radiofrequency thermal ablation of primary kidney tumors: initial experience.

Lewin JS, Nour SG, Connell CF, Sulman A, Duerk JL, Resnick MI, Haaga JR.

Radiology. 2004 Sep;232(3):835-45.

PMID:
15333798
42.
43.

Flank incision.

Resnick MI.

J Urol. 2004 Sep;172(3):823. No abstract available.

PMID:
15310974
44.

Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression.

Shukla S, MacLennan GT, Fu P, Patel J, Marengo SR, Resnick MI, Gupta S.

Neoplasia. 2004 Jul-Aug;6(4):390-400.

45.
46.

The impact of osteoporosis in men treated for prostate cancer.

Oefelein MG, Resnick MI.

Urol Clin North Am. 2004 May;31(2):313-9. Review.

PMID:
15123410
47.

Benign intrascrotal lesions.

Rubenstein RA, Dogra VS, Seftel AD, Resnick MI.

J Urol. 2004 May;171(5):1765-72. Review.

PMID:
15076274
48.

Combination conformal radiotherapy and radioimmunoguided transperineal 103Pd implantation for patients with intermediate and unfavorable risk prostate adenocarcinoma.

Ellis RJ, Vertocnik A, Sodee B, Zhou H, Kim E, Young B, Fu P, Colussi V, Spirnak JP, Dinchman KH, Resnick MI.

Brachytherapy. 2003;2(4):215-22.

PMID:
15062129
49.

Medical management of calcium oxalate urolithiasis.

Gerstenbluth RE, Resnick MI.

Med Clin North Am. 2004 Mar;88(2):431-42. Review.

PMID:
15049586
50.

Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era.

Oefelein MG, Agarwal PK, Resnick MI.

J Urol. 2004 Apr;171(4):1525-8.

PMID:
15017212

Supplemental Content

Loading ...
Support Center